Response to the letter regarding “Beyond lipid lowering: Effects of PCSK9 inhibition on inflammation and HDL function”
Journal of Clinical Lipidology · 2026-07 · 20 (7) · 1524-1525
DOI: 10.1016/j.jacl.2026.04.013 ↗Kurz gefasst
Leserbrief in der Zeitschrift Journal of Clinical Lipidology, 2026-07. Verfasst von Maximilian Seidel und 3 weiteren Autor:innen. Beteiligte Einrichtung: Medical Department 1, University Hospital Marien Hospital Herne, Ruhr-University Bochum, Germany. Electronic address: maximilian.seidel@elisabethgrup…. Die Arbeit nennt 1 Literaturangaben. Gefördert von: Novartis.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Autor:innen und Institutionen
- Medical Department 1, University Hospital Marien Hospital Herne, Ruhr-University Bochum, Germany. Electronic address: maximilian.seidel@elisabethgruppe.de.
- Medical Department 1, University Hospital Marien Hospital Herne, Ruhr-University Bochum, Germany.
Förderung
- Novartis
Zitieren
APA
Seidel, M., Seibert, F. S., Babel, N., & Westhoff, T. H. (2026). Response to the letter regarding “Beyond lipid lowering: Effects of PCSK9 inhibition on inflammation and HDL function”. Journal of Clinical Lipidology, 20(7), 1524-1525. https://doi.org/10.1016/j.jacl.2026.04.013
Vancouver
Seidel M, Seibert FS, Babel N, Westhoff TH. Response to the letter regarding “Beyond lipid lowering: Effects of PCSK9 inhibition on inflammation and HDL function”. Journal of Clinical Lipidology. 2026;20(7):1524-1525. doi:10.1016/j.jacl.2026.04.013
BibTeX
@article{Seidel2026,
author = {Seidel, Maximilian and Seibert, Felix S and Babel, Nina and Westhoff, Timm H},
title = {Response to the letter regarding “Beyond lipid lowering: Effects of PCSK9 inhibition on inflammation and HDL function”},
journal = {Journal of Clinical Lipidology},
year = {2026},
volume = {20},
number = {7},
pages = {1524--1525},
doi = {10.1016/j.jacl.2026.04.013}
}
EUVIMED